Menu
Recruiting NCT07260903

Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Controlled Trial.

No phase Interventional Age >60

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Photobiomodulation, Sham 8-weeks photobiomodulation.
Who it may be relevant to
Registry conditions: Age >60. Basic parameters: 60 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild declines in memory and concentration can reduce confidence, social participation and overall quality of life. Therefore, safe, affordable, and practical ways to help older adults remain steady on their feet and mentally sharp are urgently needed. The aim of this project is therefore to conduct a pilot feasibility randomized controlled trial to examine whether regular home-based photobiomodulation can improve balance and cognitive function in adults aged over 60. If successful, this research could help shape future strategies for preventing falls, enhancing wellbeing and maintaining independence in older people.

Interventions

  • Device Photobiomodulation
    8-weeks photobiomodulation
  • Other Sham 8-weeks photobiomodulation
    The sham device will follow the same protocol but without active light emission.

Primary outcome measures

  • n-1-back (deviation) [Time frame: Baseline]
  • n-1-back (deviation) [Time frame: 1 hour]
  • n-1-back (deviation) [Time frame: 8-weeks]
Secondary outcome measures (12)
  • n-2-back (deviation) [Time frame: Baseline]
  • n-2-back (deviation) [Time frame: 1 hour]
  • n-2-back (deviation) [Time frame: 8-weeks]
  • n-1-back (post-deviation) [Time frame: Baseline]
  • n-1-back (post-deviation) [Time frame: 1 hour]
  • n-1-back (post-deviation) [Time frame: 8-weeks]
  • n-2-back (post-deviation) [Time frame: Baseline]
  • n-2-back (post-deviation) [Time frame: 1 hour]
  • n-2-back (post-deviation) [Time frame: 8-weeks]
  • n-1-back (post-target) [Time frame: Baseline]
  • n-1-back (post-target) [Time frame: 1 hour]
  • n-1-back (post-target) [Time frame: 8-weeks]

Eligibility criteria

Inclusion criteria

  • Aged from 60-80 years
  • Ability to complete written questionnaires independently
  • Able to provide informed consent

Exclusion criteria

  • Current or past history of head injury
  • Use of medications acting on the central nervous system
  • Active skin conditions on the forehead or scalp
  • Ongoing brain stimulation therapy
  • History of migraines
  • Sensitive skin, allergies

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

United Kingdom · 1 center
  • University of Central Lancashire — Preston

Identifiers

NCT: NCT07260903 · PMB balance and cognition

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗